NCT00268671View on ClinicalTrials.gov

Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

Head and Neck Neoplasms

Interventions

DRUG

Docetaxel

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT00268671 - Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN) | Biotech Hunter | Biotech Hunter